Memantina Pentafarma (Memantine Hydrochloride)

Memantine acts as a non‑competitive antagonist of NMDA‑type glutamate receptors. By blocking excessive calcium entry through these receptors, it reduces excitotoxic neuronal damage that contributes to the neurodegenerative processes seen in Alzheimer’s disease, thereby supporting neuronal function.

The specific dose of Memantina Pentafarma is determined by the prescribing clinician based on the patient’s condition, age, renal function, and other factors. Healthcare professionals follow established guidelines and adjust the regimen as needed for safety and efficacy.

Safety data for memantine during pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss risks with their healthcare provider.

To request Memantina Pentafarma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine belongs to the NMDA receptor antagonist class, differing from cholinesterase inhibitors such as donepezil or rivastigmine. While cholinesterase inhibitors enhance acetylcholine signaling, memantine reduces glutamate‑mediated excitotoxicity. Both classes may be used together for additive benefits in certain patients, but the choice depends on disease stage and individual response.

Memantina Pentafarma should be stored at ambient temperature below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

Memantina Pentafarma is taken orally, usually once daily, with or without food as directed by the prescriber. The tablet should be swallowed whole with water and not crushed or chewed unless specifically instructed.

Serious risks include seizures, severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome, and cardiac arrhythmias. Patients should seek immediate medical attention if they experience any signs of these conditions, such as uncontrolled shaking, rash, difficulty breathing, or irregular heartbeat.

Memantina Pentafarma is contraindicated in patients with known hypersensitivity to memantine or any of its excipients. Caution is advised for individuals with severe renal impairment, uncontrolled seizures, or those taking interacting medications listed under major interactions.